Zai Lab and Entasis Complete Enrollment in Global Test of New Antibacterial
July 28, 2021 at 04:59 AM EDT
Shanghai Zai Lab and Boston 's Entasis Therapeutics have completed enrollment in a global Phase III trial of novel combination antibacterial. Entasis' SUL-DUR combines two IV antibacterial aimed at treating infections caused by Acinetobacter baumannii, including carbapenem-resistant strains. Zai enrolled one-quarter of the patients in Part A of the trial, which will evaluate the primary efficacy of the candidate. In 2018, Zai acquired China rights to SUL-DUR in a $100 million agreement. More details.... Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: ETTX) Share this with colleagues: // //
